Mycophenolate mofetil and atherosclerosis - Results of animal and human studies
Mycophenolate mofetil and atherosclerosis - Results of animal and human studies
复制标题
DOI：
10.1196/annals.1423.023
复制
发表时间：
2007-01-01
期刊：
影响因子：
--
通讯作者：
Hayden, Michael Reuben
中科院分区：
文献类型：
--
作者：
Gibson, William Thomas;Hayden, Michael Reuben
免疫抑制剂霉酚酸酯（MMF）在心脏移植患者中除了抑制组织排斥反应外还具有有益作用。与接受硫唑嘌呤治疗的患者相比，接受含MMF治疗方案的患者内膜增厚和心脏移植物血管病变减少。研究表明，饮食诱导的动脉粥样硬化（一种相关的血管病变）是一种慢性炎症过程，因此MMF也被用于降低兔高脂血症模型中的动脉粥样硬化。这些数据提供了一种有趣的可能性，即MMF可能是动脉粥样硬化显著风险人群的可行的主要或次要预防药物。
The immunosuppressive agent mycophenolate mofetil (MMF) has beneficial effects in cardiac transplant patients beyond the suppression of tissue rejection. Patients with regimens containing MMF experience diminished intimal thickening and cardiac allograft vasculopathy compared to patients treated with azathioprine. Studies have shown that diet-induced atherosclerosis (a related vasculopathy) is a chronic inflammatory process, and so MMF has also been used to reduce atherosclerosis in a rabbit model of hyperlipidemia. These data hold out the intriguing possibility that MMF might be a viable primary or secondary preventive agent in people at significant risk for atherosclerosis.